http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GR-1005058-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9162247a8bfd913bf61f7c8eb4e66208 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C275-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-06 |
| filingDate | 2004-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc8a05c29895602dcc881a858fd8cee5 |
| publicationDate | 2005-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GR-1005058-B |
| titleOfInvention | PREPARATION FOR TREATMENT OF OVERSEAS |
| abstract | hypercholesterolemia is the cause of atherosclerosis, as is the case with coronary heart disease, ischemic cerebrovascular events and peripheral vascular disease. Medicines in clinical or preclinical studies contain antagonist reductase and catalysts. Statins, which are mevinolic acids, are pharmacologically produced by fermentation of Aspergillus fungi, and hydroxy-methyloxyl-glutarol-coenzyme A is a reductase inhibitor. Patients receiving statins for treatment have been shown to have increased serum concentrations of hepatic aminotransferases. Statins also affect the liver, the visual system, and the nervous system causing it to decline, and they also cause myopathy, musculoskeletal problems, rhabdomyolysis, and ultimately morbidity and mortality. Finally, a new ornithine drug (amino acid), is unique in reducing cholesterol. |
| priorityDate | 2004-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.